Aethlon Medical Q3 net loss widens to $3.6M; expenses up 25% on CEO separation costs

AETHLON MEDICAL INC

2024-Q3 EPS reported -$3.95

Net loss of $3.6M for fiscal Q3 ended Dec 31, 2023, vs $2.8M a year ago.
Operating expenses $3.6M (+25% YoY), driven by $873K in former CEO separation costs.
Cash balance $8.0M as of Dec 31, 2023; company focusing on expense reduction.
Received DCGI clearance in India for phase 1 trial of Hemopurifier in solid tumors.
In vitro binding study results inconclusive; engaging third-party labs for independent assays.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AETHLON MEDICAL INC reported fiscal third quarter ended December 31, 2023 results: net income $3.6 million.

Period: fiscal third quarter ended December 31, 2023
Net income: $3.6 million
Result: reported results

Exact text from the filing

On February 14, 2024, Aethlon Medical, Inc. issued a press release announcing its financial results for the quarter ended December 31, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

AETHLON MEDICAL INC filing history →

Source: SEC EDGAR

accession 0001683168-24-000985

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.